In:
Antiviral Chemistry and Chemotherapy, SAGE Publications, Vol. 4, No. 6 ( 1993-12), p. 341-352
Abstract:
The syntheses of 4-amino-1-(β-D-ribofuranosyl)-1 H-1,2,3-triazolo[4,5-c]pyridine (8-aza-3-deazaadenosine, 1), 4-amino-1-(2-deoxy-β-D- erythro-pentofuranosyl)-1 H-1,2,3-triazolo[4,5-c] pyridine (2′-deoxy-8-aza-3-deazaadenosine, 2), and their N 8 and N 7 glycosylated analogues (12,13, 21,22) and 4-amino-1-(2,3-dideoxy-β-D- erythro-pentof uranosyl)-1 H-1,2,3-triazolo [4,5-c]pyridine (2′,3′-dideoxy-8-aza-3-deazaadenosine, 3) were carried out by glycosylation of the 4-chloro-3 H-1,2,3-triazolo[4,5-c] pyridine anion. The anomeric configuration as well as the position of glycosylation were determined by 1 H-, 13 C-NMR, UV and N.O.E. difference spectroscopy. Nucleoside (2) and its parent compound 2′-deoxy-3-deazaadenosine were found active against ASFV and VSV. The 4-chloro-2-(β-D-ribofuranosyl)-2 H-1,2,3-triazolo[4,5-c] pyridine (9) was active against Coxsackie B1, whereas none of the 8-aza-3-deaz a purine nucleosides, compound (3) included, was active against HIV-1. The 6-chloro derivatives of 8-aza-3-deazapurine ribo- and 2′-deoxyribonucleosides (11) and (20) showed some activity against LoVo human colon adenocarcinoma.
Type of Medium:
Online Resource
ISSN:
2040-2066
,
2040-2066
DOI:
10.1177/095632029300400606
Language:
English
Publisher:
SAGE Publications
Publication Date:
1993
detail.hit.zdb_id:
2130088-4
Permalink